Amphetamine: Side Effects, Uses & Monitoring
Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADH
- Data source
- FDA labeling via NIH DailyMed (label f6c30ba1…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Vomiting | 22% |
| General | 14% |
| Cardiovascular system | 6% |
| Fever | 5% |
| Infection | 4% |
| Metabolic/nutritional | 4% |
| Accidental injury | 3% |
| Anorexia (loss of appetite) | 2.9% |
| Asthenia (fatigue) | 2% |
| Viral infection | 2% |
| Nervousness | 2% |
| Insomnia | 1.5% |
| Weight loss | 1.2% |
| Emotional lability | 1% |
| Depression | 0.7% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules in the treatment of ADHD was established on the basis of two controlled trials in children aged 6 to 12, one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met DSM-IV® criteria for ADHD (see CLINICAL PHARMACOLOGY ), along with extrapolation from the known efficacy of ADDERALL® , the immediate-release formulation of this substance. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by anot…
Conditions associated with Amphetamine in labeling
Frequently Asked Questions
What is Amphetamine used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Amphetamine?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Amphetamine. Individual risk varies.
Does Amphetamine require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Amphetamine.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.